Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28589893 | 1.00 | TSHR (0.54) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL2383744 | 0.98 | TSHR (0.56) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL28651252 | 0.91 | TSHR (0.59) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL12658607 | 0.90 | TSHR (0.43) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL29759432 | 0.89 | CYP3A4 (0.50) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL27042152 | 0.89 | TSHR (0.68) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL21122056 | 0.89 | CYP3A4 (0.50) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL27042141 | 0.89 | TSHR (0.68) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL11849399 | 0.89 | CYP3A4 (0.50) | TSHRCYP3A4LPAR3LPAR2LPAR1 | |
| SCHEMBL27042289 | 0.89 | TSHR (0.68) | TSHRCYP3A4LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | TSHR 3960/4885CYP3A4 1936/4885LPAR3 712/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | TSHR 3960/4885CYP3A4 1936/4885LPAR3 712/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | TSHR 3960/4885CYP3A4 1936/4885LPAR3 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.